Jindal SK, Aggarwal AN, Chaudhry K, et al. A multicentric study on epidemiology of chronic obstructive pulmonary disease & its relationship with tobacco smoking and environmental tobacco exposure. Indian J Chest Dis Allied Sci 2006; 48(1): 23-9.
Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166(5): 675-9.
Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents? Circulation 2004; 109(21)(Suppl. 1): II18-26.
Fessler MB, Young SK, Jeyaseelan S, et al. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 2005; 171(6): 606-15.
Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353(9157): 983-4.
Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 100(11): 2671-9.
Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18(11): 1671-8.
Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273(37): 24266-71.
Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107(11): 1423-32.
Baccante G, Mincione G, Di Marcantonio MC, Piccirelli A, Cuccurullo F, Porreca E. Pravastatin up-regulates transforming growth factor-beta1 in THP-1 human macrophages: Effect on scavenger receptor class A expression. Biochem Biophys Res Commun 2004; 314(3): 704-10.
Schönbeck U, Gerdes N, Varo N, et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002; 106(23): 2888-93.
Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349(9063): 1436-42.
Rennard SI. Inflammation in COPD: A link to systemic comorbidities. Eur Respir Rev 2007; 16: 91-7.
Soriano JB, Maier WC, Egger P, et al. Recent trends in physician
diagnosed. COPD in women and men in the UK Thorax 2000; 55: 789-94.
Pauwels RA, Löfdahl CG, Pride NB, Postma DS, Laitinen LA, Ohlsson SV. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): Hypothesis and design. Eur Respir J 1992; 5(10): 1254-61.
Kaczmarek P, Sladek K, Skucha W, Rzeszutko M, et al. The influence of simvastatin on selected inflammatory markers in patients with COPD. Pol Arch Med Wewn 2010; 120: 1-2.
Lee TM, Lin MS, Chang NC. Usefulness of CRP and IL-6 as predictors of outcomes in patients with COPD receiving pravastatin. Am J Cardiol 2008; 101: 530-5.
Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: Findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006; 173(1): 79-83.
Lee TM, Chen CC, Shen HN, Chang NC. Effects of pravastatin on functional capacity in patients with COPD and pulmonary hypertension. Clin Sci (Lond) 2009; 116: 497-505.
Broekhuizen R, Wouters EFM, Creutzberg EC, Schols AMW. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61(1): 17-22.